Patents by Inventor Mandar Deodhar

Mandar Deodhar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230349907
    Abstract: The present invention relates to novel bioprobes which are capable of binding to certain amine oxidase enzymes. These bioprobes are useful in methods of detecting and determining the concentration of certain amine oxidase enzymes in a sample as well as in methods for the quantitative assessment of inhibition of certain amine oxidases.
    Type: Application
    Filed: February 5, 2021
    Publication date: November 2, 2023
    Applicant: Pharmaxis Ltd.
    Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Heidi Schilter Sambade, Wenbin Zhou, Lara Anne Perryman
  • Publication number: 20230257342
    Abstract: The present invention relates to novel compounds which are capable of inhibiting semicarbazide-sensitive amine oxidase (SSAO/VAP-1) and monoamine oxidase B (MAO-B). These compounds are useful for treatment of a variety of neuromuscular diseases, such as muscular dystrophies, and neuroinflammatory diseases, including both peripheral and central disorders in human subjects, as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
    Type: Application
    Filed: June 25, 2021
    Publication date: August 17, 2023
    Inventors: Alan Duncan Robertson, Alison Dorothy Findlay, Alberto Buson, Craig Ivan Turner, Dieter Wolfgang Hamprecht, Jonathan Stuart Foot, Mandar Deodhar, Wolfgang Jarolimek, Serena Becchi, Bernard Walter Balleine, Marcella Canton, Libero Vitiello, Bert Blaauw
  • Publication number: 20220251036
    Abstract: The present invention relates to methods for preparing a variety of difluorohaloallylamine derivatives. The present invention also relates to novel difluorohaloallylamine derivatives that are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for the treatment of a variety of indications, e.g., fibrosis, cancer and/or scarring in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as uses thereof.
    Type: Application
    Filed: July 24, 2020
    Publication date: August 11, 2022
    Applicant: PHARMAXIS LTD.
    Inventors: Dieter Wolfgang HAMPRECHT, Alison Dorothy FINDLAY, Craig Ivan TURNER, Mandar DEODHAR, Angelique Elsa GRECO, Wolfgang JAROLIMEK, Wenbin ZHOU
  • Publication number: 20210353571
    Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
    Type: Application
    Filed: August 2, 2019
    Publication date: November 18, 2021
    Inventors: Alison Dorothy FINDLAY, Craig Ivan TURNER, Mandar DEODHAR, Jonathan Stuart FOOT, Wolfgang JAROLIMEK, Wenbin ZHOU, Alberto BUSON, Angelique Elsa GRECO
  • Patent number: 11098045
    Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: August 24, 2021
    Assignee: Pharmaxis Ltd.
    Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
  • Publication number: 20200317666
    Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
    Type: Application
    Filed: June 11, 2020
    Publication date: October 8, 2020
    Applicant: PHARMAXIS LTD.
    Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
  • Patent number: 10717734
    Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: July 21, 2020
    Assignee: Pharmaxis Ltd.
    Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
  • Patent number: 10717733
    Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: July 21, 2020
    Assignee: Pharmaxis Ltd.
    Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
  • Publication number: 20200069648
    Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
    Type: Application
    Filed: March 2, 2018
    Publication date: March 5, 2020
    Inventors: Alison Dorothy FINDLAY, Craig Ivan TURNER, Mandar DEODHAR, Jonathan Stuart FOOT, Wenbin ZHOU, Wolfgang JAROLIMEK, Alan Duncan ROBERTSON
  • Publication number: 20190119269
    Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
    Type: Application
    Filed: February 10, 2017
    Publication date: April 25, 2019
    Applicant: PHARMAXIS LTD.
    Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
  • Publication number: 20190071396
    Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.
    Type: Application
    Filed: November 1, 2018
    Publication date: March 7, 2019
    Inventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
  • Publication number: 20190040007
    Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
    Type: Application
    Filed: February 10, 2017
    Publication date: February 7, 2019
    Applicant: PHARMAXIS LTD.
    Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
  • Patent number: 10160723
    Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: December 25, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
  • Publication number: 20180086698
    Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.
    Type: Application
    Filed: October 5, 2017
    Publication date: March 29, 2018
    Inventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
  • Patent number: 9815782
    Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: November 14, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
  • Publication number: 20160244406
    Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.
    Type: Application
    Filed: February 26, 2016
    Publication date: August 25, 2016
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
  • Patent number: 9302986
    Abstract: The preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I: is described. Methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer, are also described.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: April 5, 2016
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
  • Publication number: 20150158813
    Abstract: The preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I: is described. Methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer, are also described.
    Type: Application
    Filed: April 5, 2013
    Publication date: June 11, 2015
    Inventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan D. Robertson, Craig Ivan Turner
  • Patent number: 8426587
    Abstract: The present invention is related to the preparation and pharmaceutical use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: (I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: April 23, 2013
    Assignee: Pharmaxis Ltd.
    Inventors: Ian A. McDonald, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot
  • Publication number: 20100298330
    Abstract: The present invention is related to the preparation and pharmaceutical In use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification:(I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.
    Type: Application
    Filed: November 19, 2008
    Publication date: November 25, 2010
    Applicant: PHARMAXIS LTD.
    Inventors: Ian A. McDonald, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot